Background. The duration of antibody response following reduced human papillomavirus (HPV) vaccine doses has not been determined. We compared the antibody responses in girls previously vaccinated with zero, 1, 2, or 3 doses of quadrivalent HPV vaccine (4vHPV; Gardasil, Merck) 6 years previously.
The Cervarix (bivalent [2v] ) and Gardasil (quadrivalent [4v]) human papillomavirus (HPV) vaccines, when administered as standard 3-dose schedules, have demonstrated high vaccine efficacy (>96%) against cervical cancer precursors in HPVnaive individuals [1] [2] [3] [4] [5] , and induce high levels of type-specific antibodies that persist for at least 8 and 9 years for 4vHPV and 2vHPV, respectively [6, 7] .
Clinical studies examining reduced-dose HPV schedules found noninferior antibody responses in girls aged <15 years who receive 2 doses of either 2vHPV or 4vHPV, and women aged ≥15 years who received 3 doses of the corresponding vaccine [8] . This led the World Health Organization (WHO) in 2015 to revise its recommendation from administering 3 doses of HPV vaccine over 6 months to 2 doses provided they are 6 months apart, in girls <15 years of age [9] . However, the duration of antibody response following reduced-dose schedules has not been determined, with the longest follow-up of noninferior antibody responses following 4vHPV and 2vHPV between girls who received 2 doses (at zero and 6 months) and women who received 3 doses, of 4 and 5 years, respectively [10] [11] [12] . One dose of 2vHPV induced antibodies that persisted for at least 4 years, and also demonstrated high vaccine efficacy against incident HPV infection [13, 14] . This suggests that even a single dose of HPV vaccine may be sufficient for protection against HPV infection, although further research is needed to confirm this finding.
In 2008-2009, the Fiji Ministry of Health and Medical Services received a donation of 4vHPV based on the high burden of cervical cancer [15] . All girls aged 9-12 years were eligible to receive the 3-dose schedule recommended at that time. However, due to logistical challenges, not all girls received 3 doses of the vaccine, with some receiving only 1 or 2 doses. In 2013, the Fijian government introduced 2vHPV as a 3-dose schedule into its national immunization program, providing an opportunity to examine the immune response in girls who had received <3 doses of 4vHPV during the 2008-2009 campaign, and to ensure these girls completed 3 doses of HPV vaccine, using the nationally available 2vHPV. We aimed to determine whether girls previously vaccinated with 1 or 2 doses of 4vHPV in 2008-2009 had similar immune responses to girls who received 3 doses. Our secondary aim was to evaluate the effect of a single dose of 2vHPV in these same groups of girls. A group of girls who did not receive any HPV vaccine previously (zerodose group) were recruited as a comparison group.
METHODS

Study Design and Participants
We conducted a prospective cohort study in Fiji between February and March 2015. A total of 200 Fijian girls (now aged 15-19 years) were recruited. Each of the 4vHPV dosage groups comprised similar numbers of girls from the 2 main ethnic groups, Indigenous Fijians (iTaukei) and Fijians of Indian descent (FID).
We obtained the immunization records of the 4vHPV campaign of 2008-2009 from the Fiji Ministry of Health and Medical Services and recruited girls from these lists who had previously received 1, 2, or 3 doses of 4vHPV and lived in the Greater Suva area (Suva, Nausori, and Valelevu). The vaccination lists were ordered by the number of 4vHPV doses received previously. For each dosage group, the girls were sequentially contacted by the study nurses to participate in the study, but due to difficulties in locating girls on the vaccine list, friends of recruited girls were also approached to participate. Girls who had not received any prior 4vHPV vaccine were recruited by the recommendation of friends of recruited girls and by informal network (ie, word of mouth).
Procedures
Written informed consent or assent was obtained from all girls aged ≥18 or <18 years old, respectively. Additional written informed consent was obtained from the girl's parent/guardian for girls <18 years of age. We excluded any participant who had anaphylaxis following a previous dose of the vaccine or any vaccine component, had received 2vHPV previously, had an axillary temperature >38°C, or could possibly be pregnant.
The vaccination status of the girls was verified from the school vaccination list. A questionnaire, administered by the study staff, was completed, which included participant demographics and potential confounders. Despite being an important potential confounder, the number of sexual partners was not asked, as local investigators thought this would not be acceptable to ask in this age group. Participants were observed for any adverse events (ie, faintness; anaphylaxis or allergies; wheezing/rash) for 30 minutes following vaccination. In addition, the parents/ participants were telephoned 2-3 days following the first study visit and asked on day 28 to record any potential adverse events, including whether the participant experienced any of the following symptoms: headache, faintness, fever, fatigue, nausea, vomiting, diarrhea, loss of appetite, muscle or joint pain, redness, swelling or pain at injection site, convulsion, rash, and hospitalization, or required any sort of medical attention. Any serious adverse events (defined as any adverse event that met one of the following: death, life-threatening complication, hospitalization, or persistent/significant disability) were also documented.
Blood samples were collected to determine the immunogenicity at day 0 and 28 days following a single dose of 2vHPV (Cervarix, GlaxoSmithKline, Rixensart, Belgium: 0.5-mL monodose prefilled vial containing 20 μg each of HPV viruslike particle types 16 and 18 adjuvanted with AS04), given at day 0 to all participants to demonstrate immunological memory.
Laboratory Methods
The blood samples were separated into serum and peripheral blood mononuclear cells (PBMCs) by density gradient centrifugation. The serum samples were frozen at -80°C and the PBMCs were cryopreserved in liquid nitrogen. Both serum and PBMCs were shipped on dry ice to Murdoch Childrens Research Institute, Melbourne, Australia, for laboratory analysis.
The neutralizing antibodies (NAbs) against HPV types 6, 11, 16, and 18 were measured using the pseudovirion-based neutralization assay previously described by Barzon et al [16] . The neutralizing titer (ED 50 ) is defined as the highest serum dilution that reduces the secreted alkaline phosphatase activity by at least 50% in comparison to a control (pseudovirions without serum). A sample with an ED 50 value of ≥100 was considered HPV seropositive; seronegative samples were given a value of 50. All laboratory staff were blinded to the vaccination status of each participant, and each sample was identified according to a unique study number.
Statistical Analysis
All the participants' characteristics were double entered into a database using EpiData. The characteristics of the different dosage groups were compared using the 1-way analysis of variance test for continuous variables or compared using the χ 2 test for categorical variables. To determine socioeconomic status, a short list was made of household assets (ie, vehicle, refrigerator, computer, electricity, washing machine, and television) that were considered to be present in more affluent and less affluent households by local Fijian staff. Data on these assets were collected and possession of each asset was scored (1 or 0). This score was weighted for consistency with other assets using principal components analysis as described by Filmer et al [17] , and the median was divided into high and low scores, which represent the richer and poorer groups, respectively. The primary analysis was the comparison of the geometric mean titers (GMTs) of the HPV-specific NAb titers against HPV-6, -11, -16, and -18 in girls who previously received 1 or 2 doses of 4vHPV with girls who received 3 doses. The secondary analyses were the comparison of the NAb GMTs of 1-month post-2vHPV between girls who received 1 or 2 doses with girls who received 3 doses. In addition, we stratified the girls in each dosage group by ethnicity, and compared their NAb GMTs before and 1 month after 2vHPV within each dosage group, and between the 1-or 2-dose group and the 3-dose group. Within the 2-dose group, we stratified the girls into those who received 2 doses <6 months or ≥6 months apart, and compared their NAb GMTs before and 1 month after 2vHPV. For these analyses, we log-transformed the NAb titers and compared them using the Student t test or MannWhitney test (for comparison of NAb titers between iTaukei and FID within the zero-dose group only). All statistical analyses were performed using GraphPad Prism software, version 5.0. A P value < .05 was considered statistically significant for all analyses. To provide 80% power to detect a 30% difference in HPV antibodies with a 2-sided 5% significance level, the sample size was determined to be in a range of 26 and 47 per dosage group for HPV-16 and HPV-18, respectively, based on published data from a 5-year follow-up study [18] .
Ethics Approval
The study was approved by the Fiji National Research Ethics Review Committee, Fiji National Research Committee (2014.5.FNRERC.5.SU), as well as the Royal Children's Hospital Human Research Ethics Committee, Melbourne, Australia (34239A). The study was registered with ClinicalTrials.gov (identifier NCT02276521).
RESULTS
Of the 284 girls approached for this study, 204 were eligible (80 girls were ineligible), and among these girls, 4 girls did not have consent to participate in the study. A total of 200 girls were recruited: 66 (3-dose group); 60 (2-dose group); 40 (1-dose group); 34 (zero-dose group) (Figure 1 ). Three girls (2 from the zero-dose group and 1 girl from the 2-dose group) were lost to follow-up for the second visit. The characteristics of the study participants did not differ by dosage group, except for the girls in the zero-dose group, who were slightly older compared with girls from the 1-dose group; the time difference since last dose of 4vHPV in the 1-dose group compared with the 2-or 3-dose group; and the difference in timing of doses 1 and 2 in the 3-and 2-dose groups (Table 1 ). In addition, a higher percentage of participants in the zero-dose group attended university compared with other groups. No other variables between the groups were significantly different except for kava consumption, which was lower in the 1-dose group compared with other dosage groups. No serious or any other adverse events, including local injection site reactions listed above, were observed following 2vHPV.
The number of girls from each dosage group who were seropositive for each HPV type 6 years since the last dose of 4vHPV are shown in Table 1 . A dose-response in NAb titers (highest in the 3-dose group) was observed across all 4 HPV types ( Figure 2) . No significant differences in the GMTs across all 4 HPV types were found between girls who previously received 2 or 3 doses of 4vHPV (HPV-6, P = .074; HPV-11, P = .086; HPV-16, P = .887; HPV-18, P = .885). Girls who had received 1 dose of 4vHPV had significantly lower GMTs for all 4 HPV types compared with girls who received 2 or 3 doses, but their NAb titers for all 4 HPV types were still 5-to 30-fold higher than unvaccinated girls.
To determine whether there is a difference in immunological memory following reduced-dose HPV schedules, a dose of 2vHPV was given to all girls in the study. The NAb titers for HPV-16 and -18 in the 1-dose group increased 46-and 84-fold following 2vHPV, respectively, to a level that was not significantly different between the 2-and 3-dose groups (Figure 3) . The NAb levels for HPV-6 and -11 were not significantly different after a dose of 2vHPV for all groups.
To determine the impact of the spacing between the first and second 4vHPV dose on NAb titers, we stratified girls in the 2-dose group into those who received their second dose <6 months or ≥6 months apart. No significant differences were seen for all 4 HPV types before or after a dose of 2vHPV (Supplementary Figure 1) .
To determine whether there is a difference in NAb responses between ethnic groups, we stratified girls by ethnicity. Significantly higher NAb titers for all 4 HPV types were seen in FID compared with iTaukei in the 2-or 3-dose groups, 6 years following 4vHPV vaccination (Supplementary Table 1 ). This observation was consistent following 1 dose of 2vHPV, except for HPV-18 or -11 in the 2-dose group. The NAb titers among iTaukei in the 3-dose group for HPV-16 and -18 were not significantly different compared with iTaukei in the 1-dose group (HPV-16, P = .279; HPV-18, P = .959) 6 years after 4vHPV vaccination, whereas FID had significantly higher NAb titers in the 3-dose group compared with FID in the 1-dose group (HPV-16 and -18, P < .0001). In addition, FID in the 2-dose group had significantly higher NAb titers compared with iTaukei in the 3-dose group before (HPV-16, P = .0003 and HPV-18, P = .002) and after (HPV-16, P = .02 and HPV-18, P = .002) 2vHPV.
DISCUSSION
To our knowledge, this is the first study to show evidence of persistent antibody levels 6 years after 1 dose of 4vHPV, and the generation of a robust memory response following only 1 dose of 4vHPV. Two doses of 4vHPV provided similar NAb titers against HPV-6, -11, -16, and -18 as 3 doses. Although girls in the 1-dose group had lower NAb titers than girls in the 2-or 3-dose groups, their levels were still higher than unvaccinated girls. Moreover, 1 month following a dose of 2vHPV, girls vaccinated with 1 dose of 4vHPV 6 years previously mounted an anamnestic antibody response to a level that was similar to girls who received 2 or 3 doses, suggesting that sufficient immune responses had been induced after 1 dose of 4vHPV. It has been suggested that 1 dose of HPV vaccine might be sufficient to protect against vaccine-type HPV infection, although the evidence is limited. A multicenter prospective cohort study in India examined the immunogenicity and HPV infection rates in girls following 1, 2, or 3 doses of 4vHPV up to 4.7 years, and found similar vaccine efficacies against persistent infection with HPV-6, -11, -16, and -18 regardless of the number of 4vHPV doses given despite lower antibody levels in girls given 1 dose of 4vHPV compared with girls who received 2 or 3 doses [11] . One dose of 2vHPV was also shown to induce antibody responses that persisted for + Two girls from the zero-dose group were excluded from the analysis as we found high levels of neutralizing antibody titers against all 4 human papillomavirus (HPV) types in visit 1, and subsequently learned that they had lived in overseas countries where HPV was on the national schedule; we assumed they received HPV vaccine previously and therefore their names were not on the school vaccination lists when they were recruited. Abbreviations: 2vHPV, bivalent human papillomavirus vaccine; FID, Fijians of Indian descent; HPV, human papillomavirus; IT, Indigenous Fijians (iTaukei). at least 4 years, and were at least 9 and 5 times higher for HPV-16 and -18, respectively, than naturally infected individuals [13] . A combined post hoc analysis of two phase 3 clinical trials (Costa Rica Vaccine Trial and PATRICIA; PApilloma TRIal against Cancer In young Adults trial) also found similar vaccine efficacy against incident HPV-16/-18 infection between individuals who were vaccinated with 1, 2, or 3 doses of 2vHPV [14] . These studies, and our data, provide the basis for assessing vaccine efficacy against HPV infection following a 1-dose HPV vaccine schedule. Noninferior antibody responses that persist for up to 4 and 5 years have been documented for both 4vHPV and 2vHPV, respectively, in girls <15 years of age who received 2 doses administered 6 months apart, compared with women aged 15-26 years who received 3 doses [8, [10] [11] [12] [19] [20] [21] [22] [23] . Our data extend these findings, showing that similar immunogenicity between 2 and 3 doses may persist for at least 6 years. A randomized, phase 3, noninferiority study by Dobson et al found inferior antibody responses for HPV-18 and HPV-6 after 24 and 36 months, respectively, in girls aged 9-13 years receiving 2 doses of 4vHPV 6 months apart compared with girls who received the standard 3-dose 4vHPV schedule [12] . Although our study was not powered for noninferiority analysis, we did observe inferior NAb titers against HPV-6 and -11, but not HPV-16 and -18 in the 2-dose group compared with the 3-dose group, using the noninferiority criteria (the lower bound of the 95% confidence interval of the GMT ratio between 2 vs 3 doses was >0.5). The clinical significance of this is unknown, and confirmation of this effect will be needed in studies with larger sample sizes. A cohort study in Sweden examined the occurrence of Figure 2 . Neutralizing antibody (NAb) titers against human papillomavirus (HPV) types 16, 18, 6, and 11, six years after last dose of quadrivalent HPV vaccine (4vHPV). Doseresponse was seen across all dosage groups for all 4 HPV types. There was no significant difference between the 2-and 3-dose groups. The 1-dose group had significantly lower NAb titers than the 2-and 3-dose groups, but significantly higher than the zero-dose group. Error bars represent geometric mean titer ± 95% confidence interval. *P < .05; **P < .01; ***P < .001. Abbreviations: ED 50 , effective dose 50; PSV, pseudovirion. Socioeconomic status was derived using principal component analysis of household assets (derived from local inquiry) as described in [17] . Based on the weighted scores from the 3 most correlated assets, a single numeric score was derived; the score was divided into upper and lower median scores, which represent the richer and poorer groups, respectively. Table 1 . Continued genital warts (typically caused by HPV-6 and -11) and vaccination with varying doses of 4vHPV in women aged 10-24 years, and found that girls (10-19 years old, mean follow-up of 3.8 years) vaccinated with fewer than three 4vHPV doses had an increased incidence rate compared with girls vaccinated with 3 doses [24] . Whether reduced-dose HPV vaccination is effective against genital warts in the long term remains to be elucidated.
Ethnicity has been shown to affect the immune response to other vaccines (ie, influenza, hepatitis B, and rubella) [25] [26] [27] . In Fiji, the 2 main ethnic groups are the iTaukei and FID. We found that, in general, FID had higher NAb titers than iTaukei 6 years following 4vHPV vaccination, and also after a "booster" dose of 2vHPV. The precise mechanism for this is unknown, and could be due to genetic factors or differing prevalence of HPV infection. Another possible suggestion could be the body mass index (BMI) of the girls in the ethnic groups, as studies on hepatitis B vaccination have found that higher BMI is associated with poorer immune responses [28] . Although we did not observe a significant difference in the BMI between dosage groups, significantly higher BMI was observed in iTaukei than in FID within the 2-and 3-dose groups, as well as the whole cohort (data not shown), which may explain some of the ethnic differences we found in the immune responses.
We did not detect any significant differences in NAb titers when the second dose was given <6 months or ≥6 months apart in the 2-dose group, although our study was underpowered for this analysis. Higher immunogenicity is usually observed when the timing of the second dose is >6 months [11, 14, 19, 20] ; however, vaccine efficacy against HPV-16/-18 incident infections has not been shown to be different in this context.
A unique aspect of our study was the ability to examine the safety and immunogenicity of mixed HPV vaccine schedules comprising both 4vHPV and 2vHPV. The fact that we did not observe any increase in HPV-6 and -11 NAbs following 2vHPV is not unexpected, as these 2 types differ phylogenetically from HPV-16 and -18 [29] . No adverse reactions were documented in our study, with only minor adverse events not requiring medical intervention observed in a previous study of mixed HPV vaccine schedules [30] , providing confidence on the safety and possible use of mixed HPV vaccine schedules. Given that the Gardasil 9 vaccine (9vHPV) is now being licensed in more countries globally, the safety of mixed HPV vaccine schedules is therefore relevant for countries transitioning from either 4vHPV or 2vHPV schedules to 9vHPV [31] . It is worth noting that girls who received an initial series of 2 or 3 doses are not recommended to be boosted routinely, rather that this was done for the purpose of this study.
The major limitations of our study were the small sample size and the study design, which includes potential selection bias as reflected in the differences in participants' age and education at enrollment. Another limitation in our study was the lack of HPV infection data, including information on participants' sexual behaviors (ie, whether they have had sexual relationships and the number of sexual partners), which are potential confounders that may affect the antibody response.
In conclusion, our results lend support to the WHO recommendation of 2 doses of HPV vaccine for young girls, and contribute to the growing evidence of the possibility of longterm protection against HPV following 1 dose of HPV vaccine. Furthermore, it would seem safe to use both vaccines within an individual. Further studies that specifically address the issue Figure 3 . Neutralizing antibody (NAb) titers against human papillomavirus (HPV) types 16, 18, 6, and 11, one month after a "booster" dose of bivalent HPV vaccine (2vHPV). Post 2vHPV NAb titers were significantly higher for HPV-16 and -18 than pre-2vHPV NAb titers for all dosage groups (P < .001). No significant differences in NAb titers were shown for HPV-6 and -11 between pre-and post-2vHPV. Error bars represent geometric mean titers ± 95% confidence interval. Abbreviations: ED 50 , effective dose 50; PSV, pseudovirion.
of single-dose HPV schedules and long-term protection are warranted. In terms of how these immunogenicity findings translate into preventing HPV infection, we currently have a follow-up study in young pregnant women to determine HPV detection rates by HPV dosage group. Fiji has since moved to a 2-dose 2vHPV schedule, with a gap of 6 months between doses.
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